|
Dr. Schwartz joined ArQule in July 2008 from Ziopharm Oncology Inc. where as senior vice president clinical and regulatory affairs and chief medical officer he built and led clinical regulatory and quality assurance departments responsible for the development of new cancer drugs. Prior to Ziopharm Dr. Schwartz held a number of positions at Bayer Healthcare. His experience in oncology has encompassed the clinical development of novel cytostatic cytotoxic and immunological agents. At Bayer Dr. Schwartz was a key physician responsible for the global clinical development of sorafenib (Nexavar®) and led the clinical team through a successful Phase 3 trial in renal cell cancer leading to U.S. Food and Drug Administration (FDA) approval. He has extensive regulatory experience working with the FDA’s Oncology Division the European Medicines Evaluation Agency (EMEA) and numerous other health authorities. Dr. Schwartz has also been responsible for U.S. clinical and regulatory activities including Phase 4 studies and interactions with the National Cancer Institute and other oncology cooperative groups. Dr. Schwartz received his medical degree from the University of Pretoria South Africa practiced medicine and worked at the University of Toronto prior to his career in industry.
| 